Boosting SIV-specific CD8+ T cell responses prior to ART interruption extends time to SIVmac239 rebound

Journal:

Journal of Clinical Investigation

Published:

2026-01-29

DOI:

10.1172/jci198294

Affiliations:

6

Authors:

30

Go to article

Institutions	Authors	Share
Oregon Health and Science University (OHSU), United States of America (USA)	10.000000 10.000000	0.33
Frederick National Laboratory for Cancer Research (FNLCR), United States of America (USA)	10.000000 10.000000	0.33
Oregon National Primate Research Center (ONPRC), United States of America (USA)	5.000000	0.17
CureVac GmbH, Germany	3.000000	0.10
Fred Hutchinson Cancer Center, United States of America (USA)	2.000000	0.07

Interested in Clinical Sciences?